Results 121 to 130 of about 143,834 (286)

ANTISENSE MEDIATED DYSTROPHIN READING FRAME RESTORATION [PDF]

, 2010
Exon skipping using antisense oligonucleotides (AONs) has successfully been used to reframe the mRNA in various DMD (Duchenne muscular dystrophy) patients carrying deletions and in the mdx mouse model.
Spitali, Pietro
core  

Non-hybridisation saturable mechanisms play a role in the uptake of 68Ga-labelled LNA-DNA mixmer antisense oligonucleotides in rats

, 2009
Oligonucleotides (ODN) are key molecules for the aim of preventing   translation of a gene product or monitoring gene expression in tissues.   However, multiple methodological and biological hurdles need to be   solved before in vivo application in ...
Josephsson, Raymond, Bergström, Mats,, Eriksson, Barbro,, Monazzam, Azita,, Estrada, Sergio, Velikyan, Irina, Lendvai, Gabor,, Långström, Bengt,   +7 more
core   +1 more source

2′-OMe antisense oligonucleotides.

, 2015
2′-OMe antisense oligonucleotides.
Agnieszka Gorska (482400), Mariola Dutkiewicz (7006), Paulina Zydowicz (819770), Julia Suchacka (819771), Jerzy Ciesiołka (7007), Agata Swiatkowska (482401)   +5 more
core   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Antisense oligonucleotides used in this study.

, 2013
Antisense oligonucleotides used in this study.
Willem M. H. Hoogaars (430632), Annemieke Aartsma-Rus (33030), Jie Cai (389349), SongTing Shi (430629), Dwi U. Kemaladewi (430631), Peter A. C. ’t Hoen (5655445), David J. J. de Gorter (408007), Gonzalo Sanchez-Duffhues (430630), Peter ten Dijke (82259)   +8 more
core   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Splicing therapeutics in SMN2 and APOB [PDF]

, 2009
Splicing therapeutics are defined as the deliberate modification of RNA splicing to achieve therapeutic goals. Various techniques for splicing therapeutics have been described, and most of these involve the use of antisense oligonucleotide-based ...
Krainer, AR, Khoo, B., Krainer, A. R., Khoo, B   +3 more
core  

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

British Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis, Christine Leopold, Joyce M. Hoek, Raymond M. Schiffelers, Marie L. De Bruin   +4 more
wiley   +1 more source

4′‐ThioRNA Substitution and Sense‐Strand Segmentation for the Design of Functional Fully Modified siRNAs Targeting SARS‐CoV‐2

Chemistry – A European Journal, EarlyView.
4′‐ThioRNA was broadly tolerated across multiple positions in SARS‐CoV‐2‐targeting siRNAs, but full 4'‐thio modification of both strands caused a reduction in RNAi activity. Sense‐strand segmentation improved RNAi and antiviral activity, particularly when the nick was located at position 10 from the 5′‐end of the sense strand, thereby unlocking the ...
Yuhei Nogi, Jun Tsukimoto, Noriko Saito‐Tarashima, Takaaki Koma, Masako Nomaguchi, Noriaki Minakawa   +5 more
wiley   +1 more source